

1-1-2006

Synthesis and Antimicrobial Activity of Some New 3-Substituted Benzyl-5-(4-chloro-2-piperidin-1-yl-thiazole-5-yl-methylene)-thiazolidine-2,4-dione Derivatives

MELTEM CEYLAN ÜNLÜSOY

OYA BOZDAĞ DÜNDAR

NURTEN ALTANLAR

RAHMİYE ERTAN

Follow this and additional works at: <https://journals.tubitak.gov.tr/chem>

 Part of the [Chemistry Commons](#)

Recommended Citation

ÜNLÜSOY, MELTEM CEYLAN; DÜNDAR, OYA BOZDAĞ; ALTANLAR, NURTEN; and ERTAN, RAHMİYE (2006) "Synthesis and Antimicrobial Activity of Some New 3-Substituted Benzyl-5-(4-chloro-2-piperidin-1-yl-thiazole-5-yl-methylene)-thiazolidine-2,4-dione Derivatives," *Turkish Journal of Chemistry*. Vol. 30: No. 3, Article 10. Available at: <https://journals.tubitak.gov.tr/chem/vol30/iss3/10>

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for inclusion in Turkish Journal of Chemistry by an authorized editor of TÜBİTAK Academic Journals. For more information, please contact academic.publications@tubitak.gov.tr.

Synthesis and Antimicrobial Activity of Some New 3-Substituted Benzyl-5-(4-chloro-2-piperidin-1-yl- thiazole-5-yl-methylene)-thiazolidine-2,4-dione Derivatives

Meltem CEYLAN ÜNLÜSOY¹, Oya BOZDAĞ DÜNDAR^{1*},
Nurten ALTANLAR² and Rahmiye ERTAN¹

¹Ankara University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry
Tandoğan, Ankara-TURKEY

e-mail: bozdag@pharmacy.ankara.edu.tr

²Ankara University, Faculty of Pharmacy, Departments of Microbiology
Tandoğan, Ankara-TURKEY

Received 15.12.2005

A new series of thiazolyl thiazolidine-2,4-dione (**Va-f**) were synthesized and their structures were elucidated by IR, ¹H-NMR, mass spectra and elementary analysis. The synthesized compounds were tested for their antimicrobial activities against *Candida albicans*, *Staphylococcus aureus*, *Bacillus subtilis* and *Escherichia coli*. Compounds **Va-b**, **Vd-f** showed high activity against *Escherichia coli* comparable to ampicillin.

Key Words: Thiazolidine-2,4-diones, thiazole derivatives, antimicrobial activities.

Introduction

The presence of a thiazolidine ring in penicillins and related derivatives was the first recognition of its occurrence in nature ¹. Thiazolidine derivatives are reported to show a variety of biological activities. Depending on the substituents, this heterocycle can induce different pharmacological properties such as antibacterial, antifungal², antidiabetic^{3,4}, cardiotoxic⁵, anticonvulsant⁶, cyclooxygenase and lipoxygenase inhibitory⁷. Thiazoles and their derivatives have been reported to possess antibacterial⁸, and antifungal⁹ activities. It has been established that the introduction of arylidene moieties at different positions of the thiazolidine ring enhanced antimicrobial activity^{2,10}. In the present study, in view of the antimicrobial property of the above pharmacophores, some novel thiazole derivatives that contain thiazolidinedione moiety were synthesized.

*Corresponding author

Experimental

Melting points were determined with a Büchi SMP-20 melting point apparatus and were uncorrected. All instrumental analyses were performed in the Central Laboratory of the Pharmacy Faculty of Ankara University. IR spectra were recorded on a Jasco FT/IR-420 spectrometer as potassium bromide disks. ¹H NMR spectra were measured with a VARIAN Mercury 400 FT-NMR spectrometer in CDCl₃ and DMSO-d₆. All chemical shifts were reported as δ (ppm) values. Mass spectra were recorded on VG Waters Micromass ZQ by the ESI (+) method. Elementary analyses were performed on a Leco CHNS 932 analyzer and satisfactory results ±0.4% of calculated values (C, H, N) were obtained. For the chromatographic analysis Merck Silica Gel 60 (230-400 mesh ASTM) was used. The chemical reagents used in the synthesis were purchased from E. Merck (Darmstadt, Germany) and Aldrich (Milwaukee, MI, USA). 2,4-TZD (**I**)², 2,4-dichlorothiazole-5-carbaldehyde (**II**)¹¹, 4-chloro-2-piperidin-1-yl-thiazole-5-carbaldehyde (**III**)¹² and substituted-2,4-TZD (**IVa-f**)^{2,13,14} were synthesized according to the literature.

General procedure for the synthesis of compounds Va-f

Synthesis of 2,4-dichlorothiazole-5-carbaldehyde (II)

2,4-Dichlorothiazole-5-carbaldehyde (**II**) was prepared with N,N-Dimethylformamide (0.021 mol) and a suspension of 2,4-TZD (**I**) (0.021 mol) in phosphoryl chloride (0.129 mol), m.p.: 48 °C (Ref. 11 m.p.: 48-49 °C).

Synthesis of 4-chloro-2-piperidin-1-yl-thiazole-5-carbaldehyde (III)

To a stirred suspension of 2,4-dichlorothiazole-5-carbaldehyde (**II**) (0.001 mol) and potassium carbonate (0.001 mol) in acetonitrile (5 mL) was added piperidine (0.001 mol), followed by stirring for 3 h at room temperature. The product was purified by column chromatography silica gel 60 (230-400 mesh ASTM) using hexane:dichloromethane (1:1) as eluent, m.p.: 88 °C (Ref. 12 m.p.: 88-90 °C).

Synthesis of compounds IVa-f

A mixture of 2,4-TZD (**I**) (2.34 g, 0.02 mol), substituted benzyl halide (0.02 mol) and sodium hydroxide (0.8 g, 0.02 mol) in 20 mL of 50% ethanol was refluxed for 18 h. The crude product was crystallized from ethanol. [**IVa** m.p.: 62-63 °C (Ref. 12 m.p.: 61 °C), **IVb** m.p.: 83 °C (Ref. 2 m.p.: 82 °C), **IVc** m.p.: 96 °C (Ref. 13 m.p.: 97-98 °C), **IVd** m.p.: 91 °C (Ref. 14 m.p.: 90-91 °C), **IVe** m.p.: 72 °C (Ref. 13 m.p.: 68.5-70.5 °C), **IVf** m.p.: 117 °C (Ref. 13 m.p.: 117-118 °C)].

Synthesis of compounds Va-f

A mixture of 4-chloro-2-piperidin-1-yl-thiazole-5-carbaldehyde (**III**) (0.001 mol) and **IVa-f** (0.001 mol) was heated at 130-140 °C in the presence of 0.5 mL of acetic acid glacial and sodium acetate (0.001 mol) for 5 h. The reaction mixture was extracted with CHCl₃ (3 × 50 mL) and the organic layer was washed with water, dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue was purified by column chromatography silica gel 60 (230-400 mesh ASTM) using hexane:dichloromethane (1:1) as eluent.

3-Benzyl-5-(4-chloro-2-piperidin-1-yl-thiazole-5-yl-methylene)-thiazolidine-2,4-dione (Va)

React. Time: 21 h, Yield: 27.47%, m.p.: 151 °C, IR (KBr) cm^{-1} : 1733 ($\text{C}^4=\text{O}$), 1685 ($\text{C}^2=\text{O}$), ^1H NMR (DMSO- d_6): δ = 1.62 (s, 6H, a), 3.57 (s, 4H, b), 4.80 (s, 2H, CH_2), 7.28-7.36 (m, 5H, Ar-H), 7.80 (s, 1H, =CH), MS (ESI) m/z (rel. intensity): 420 (M+H, 90%).

Anal. for $\text{C}_{19}\text{H}_{18}\text{ClN}_3\text{O}_2\text{S}_2$: Calc. C: 54.34, H: 4.32, N: 10.01, S: 15.27. Found C: 54.35, H: 4.29, N: 9.84, S: 15.25.

3-(4-Fluoro-benzyl)-5-(4-chloro-2-piperidin-1-yl-thiazole-5-yl-methylene)-thiazolidine-2,4-dione (Vb)

React. Time: 5 h, Yield: 34.10%, m.p.: 152 °C, IR (KBr) cm^{-1} : 1735 ($\text{C}^4=\text{O}$), 1686 ($\text{C}^2=\text{O}$), ^1H NMR (DMSO- d_6): δ = 1.62 (s, 6H, a), 3.56 (s, 4H, b), 4.79 (s, 2H, CH_2), 7.16-7.21 (m, 2H, 2', 6'-H), 7.34-7.37 (m, 2H, 3', 5'-H), 7.78 (s, 1H, =CH), MS (ESI) m/z (rel. intensity): 438 (M+H, 90%). Anal. for $\text{C}_{19}\text{H}_{17}\text{ClFN}_3\text{O}_2\text{S}_2$: Calc. C: 52.11, H: 3.91, N: 9.59, S: 14.64. Found C: 52.12, H: 3.88, N: 9.71, S: 14.43.

3-(4-Chloro-benzyl)-5-(4-chloro-2-piperidin-1-yl-thiazole-5-yl-methylene)-thiazolidine-2,4-dione (Vc)

React. Time: 8 h, Yield: 45.74%, m.p.: 137 °C, IR (KBr) cm^{-1} : 1740 ($\text{C}^4=\text{O}$), 1681 ($\text{C}^2=\text{O}$), ^1H NMR (DMSO- d_6): δ = 1.62 (s, 6H, a), 3.57 (s, 4H, b), 4.79 (s, 2H, CH_2), 7.32 (d, 2H, 2', 6'-H), 7.42 (d, 2H, 3', 5'-H), 7.78 (s, 1H, =CH), MS (ESI) m/z (rel. intensity): 454 (M+H, 90%). Anal. for $\text{C}_{19}\text{H}_{17}\text{Cl}_2\text{N}_3\text{O}_2\text{S}_2$: Calc. C: 50.22, H: 3.77, N: 9.25, S: 14.11. Found C: 50.12, H: 3.69, N: 9.24, S: 14.48.

3-(4-Bromo-benzyl)-5-(4-chloro-2-piperidin-1-yl-thiazole-5-yl-methylene)-thiazolidine-2,4-dione (Vd)

React. Time: 9 h, Yield: 71.67%, m.p.: 169 °C, IR (KBr) cm^{-1} : 1739 ($\text{C}^4=\text{O}$), 1679 ($\text{C}^2=\text{O}$), ^1H NMR (DMSO- d_6): δ = 1.63 (s, 6H, a), 3.57 (s, 4H, b), 4.78 (s, 2H, CH_2), 7.26 (d, 2H, 2', 6'-H), 7.55 (d, 2H, 3', 5'-H), 7.79 (s, 1H, =CH), MS (ESI) m/z (rel. intensity): 498 (M+H, 65%). Anal. for $\text{C}_{19}\text{H}_{17}\text{BrClN}_3\text{O}_2\text{S}_2$: Calc. C: 45.75, H: 3.43, N: 8.42, S: 12.86. Found C: 45.28, H: 3.29, N: 8.46, S: 12.66.

3-(2,4-Dichloro-benzyl)-5-(4-chloro-2-piperidin-1-yl-thiazole-5-yl-methylene)-thiazolidine-2,4-dione (Ve)

React. Time: 13 h, Yield: 54.27%, m.p.: 217 °C, IR (KBr) cm^{-1} : 1734 ($\text{C}^4=\text{O}$), 1677 ($\text{C}^2=\text{O}$), ^1H NMR (CDCl_3): δ = 1.71 (s, 6H, a), 3.59 (s, 4H, b), 4.97 (s, 2H, CH_2), 7.13 (d, 1H, $j_{2',3'}=8.80$ Hz, 2'-H), 7.20 (dd, 1H, $j_{3',2'}=8.40$ Hz, $j_{3',5'}=2.00$ Hz, 3'-H), 7.39 (d, 1H, $j_{5',3'}=2.00$ Hz, 5'-H), 8.04 (s, 1H, =CH), MS (ESI) m/z (rel. intensity): 488 (M+H, 18%).

Anal. for $\text{C}_{19}\text{H}_{16}\text{Cl}_3\text{N}_3\text{O}_2\text{S}_2$: Calc. C: 46.68, H: 3.30, N: 8.60, S: 13.12. Found C: 46.54, H: 3.24, N: 8.46, S: 12.68.


3-(4-Nitro-benzyl)-5-(4-chloro-2-piperidin-1-yl-thiazole-5-yl-methylene)-thiazolidine-2,4-dione (Vf)

React. Time: 19 h, Yield: 59.55%, m.p.: 197 °C, IR (KBr) cm^{-1} : 1729 ($\text{C}^4=\text{O}$), 1666 ($\text{C}^2=\text{O}$), ^1H NMR (DMSO- d_6): δ = 1.63 (s, 6H, a), 3.58 (s, 4H, b), 4.95 (s, 2H, CH_2), 7.57 (d, 2H, 2', 6'-H), 7.81 (s, 1H, =CH),

8.21 (d, 2H, 3', 5'-H), MS (ESI) m/z (rel. intensity): 465 (M+H, 90%). Anal. for $C_{19}H_{17}ClN_4O_4S_2$: Calc. C: 49.08, H: 3.69, N: 12.05, S: 13.79. Found C: 48.69, H: 3.61, N: 11.98, S: 14.11.

Antimicrobial activity

The disk diffusion method was used for assessing antibacterial activity against *Staphylococcus aureus* ATCC 250 (American Type Culture Collection, Manassas, VA, USA), and *Escherichia coli* RSKK 313 (Refik Saydam Kültür Koleksiyon, Ankara, Turkey), and antifungal activity against *Candida albicans* RSKK 628 (Refik Saydam Kültür Koleksiyon, Ankara, Turkey). Cultures of each bacteria and yeast strain, kept in Mueller-Hinton broth (Difco, Detroit, MI, USA) at 37 °C for 18-24 h and diluted with the same broth to 10^5 cfu/mL, were pipetted into Mueller-Hinton agar (Difco) plates prepared according to the following procedure. Paper disks (8 mm in diameter) embedded into 3000 $\mu\text{g/mL}$ compound solution were put onto the surface of the inoculated plates, which were placed in an incubator at 37 °C for 18-24 h and then examined. Most of the compounds were found to be effective against the tested microorganisms by measuring the diameter of the growth inhibition zone according to Bauer et al.¹⁵.



Scheme. General synthesis of **Va-f**.


Results and Discussion

2,4-TZD (**I**) was synthesized with ClCH_2COOH and thiourea in hot water². 2,4-Dichlorothiazole-5-carbaldehyde (**II**) was obtained with 2,4-TZD (**I**) and N,N-dimethylformamide in phosphoryl chloride¹¹. 4-Chloro-2-piperidin-1-yl-thiazole-5-carbaldehyde (**III**) was prepared with 2,4-dichlorothiazole-5-carbaldehyde (**II**) and piperidine in acetonitrile/potassium carbonate¹². Substituted benzyl-2,4-thiazolidinediones (**IVa-f**)^{2,13,14} were obtained by 2,4-TZD (**I**) with appropriate benzyl halide derivatives in NaOH/ethanol. Thiazolyl-2,4-thiazolidinediones (**Va-f**) were prepared via a Knoevenagel reaction between the 4-chloro-2-piperidin-1-yl-thiazole-5-carbaldehyde (**III**) and appropriate substituted-2,4-thiazolidinedione (**IVa-f**) in the presence of sodium acetate/acetic acid glacial (Scheme).

The structure of the synthesized thiazolylthiazolidinedione compounds was elucidated by elementary analysis, ¹H NMR, Mass and IR findings. All spectral data were in accordance with the assumed structures. IR spectra of the compounds (**Va-f**) showed 2,4-TZD $\text{C}^4=\text{O}$ and $\text{C}^2=\text{O}$ stretching bonds at $1729\text{-}1740\text{ cm}^{-1}$ and $1666\text{-}1686\text{ cm}^{-1}$, respectively. In ¹H NMR spectra, benzylic CH_2 protons were seen at 4.78-4.97 ppm as a singlet. Aromatic protons were observed at 7.13-8.21 ppm; methylene protons of thiazolyl-2,4-TZDs were seen at 7.78-8.04 ppm as a singlet. In mass spectra, all the compounds have an M+H ion peak with the MS ESI method.

All of the new thiazolyl-2,4-thiazolidinedione compounds were tested for their antimicrobial activity by the agar diffusion method¹⁵, using *Candida albicans*, *Staphylococcus aureus*, *Bacillus subtilis* and *Escherichia coli*, and comparing with miconazole and ampicillin (Table). The resulting inhibition zones against *Bacillus subtilis*, *Staphylococcus aureus* and *Escherichia coli* were 10-12, 9-14 and 9-13 mm, respectively. As seen in the Table, compounds (**Va-b**, **Vd-f**) showed high activity against *Escherichia coli* (12, 11, 10, 11, 10 and 13 mm, respectively) comparable to ampicillin (10 mm). Compounds (**Va-f**) were found to be inactive against *Candida albicans*. The starting carbaldehyde compound (**III**) for (**Va-f**) was active against all the microorganisms tested.

Table. Antimicrobial activities ^{a)} of the compounds **Va-f**.



Compound	Y	Y ₁	<i>C. albicans</i>	<i>S. aureus</i>	<i>E. coli</i>	<i>B. subtilis</i>
Va	H	H	*	10	12	10
Vb	F	H	*	9	11	10
Vc	Cl	H	*	12	9	12
Vd	Br	H	*	14	10	11
Ve	Cl	Cl	*	14	11	12
Vf	NO ₂	H	*	12	10	12
III			10	12	13	10
Miconazole			25	-	-	-
Ampicillin			-	22	10	23

^{a)}Growth inhibition diameter (mm). *No activity. - Not tested

Acknowledgment

This work was supported by the Research Organization of Ankara University, Turkey (No: 2005-0803048).

References

1. F.C. Brown, **Chem. Rev.** **61**, 463-521 (1961).
2. M.C.A. DeLima, D.L.B. Costa, A.J.S. Goes, S.L. Galdino, I.R. Pitta and C. Luu-Duc, **Pharmazie** **47**, 182-184 (1992).
3. M. Strumvoll and H.U. Haring, **Ann. Med.** **34**: 217-222 (2002).
4. O. Bozdağ-Dündar, E.J. Verspohl, A. Waheed and R. Ertan, **Arzneim.-Forsch./Drug Res.** **53**, 831-836 (2003).
5. A. Andreani, M. Rambaldi, A. Locatelli, R. Leoni, M. Bossa, I. Chiericozzi, G. Galatulas and A. Salvatore, **Eur. J. Med. Chem.** **28**, 825-829 (1993).
6. S.A.H. El-Feky, **Pharmazie** **48**, 894-896 (1993).
7. P.C. Unangst, D.T. Connor, W.A. Cetenko, R.J. Sorenson, J.C. Sircar, C.D. Wright, D.J. Schrier and R.D. Dyer, **Bioorg. Med. Chem. Lett.** **3**, 1729-1734 (1993).
8. R.C. Sup, R.Y. Sup and C.W. Bang, **Korean J. Med. Chem.** **5**, 72-75 (1995).
9. N. Agarwal, S. Kumar, A.K. Srivastava and P.C. Sarkar, **Ind. J. Het. Chem.** **6**, 291-294 (1997).
10. I.M. Labouta, H.M. Salama, N.H. Eshba, O. Kader and E. El-Chrbini, **Eur. J. Med. Chem.** **22**, 485-489 (1987).
11. S. Athmani, M. F. Farhat, B. and J. Iddon, **Chem. Soc. Perkin Trans.** **1**, 973-977 (1992).
12. N. Debski, W. Hanefeld and M. Schlitzer, **J. Heterocyclic Chem.** **34**, 1427-1429 (1997).
13. C. Lo and E.Y. Shropshire, **J. Org. Chem.** **22**, 999-1001 (1957).
14. D.L.B. Costa, J. Chantarel, M.C. Alves DeLima, J.F.C. Albuquerque, R.M.O. Lima, S.L. Galdino, I.R. Pitta and C. Luu-Duc, **J. Pharm. Belg.** **50**, 5-10 (1995).
15. A.W. Bauer, W.M.M. Kirby, J.C. Sherris and M. Turck, **Am. Clin. Pathol.** **45**, 493-496 (1966).